SkinBioTherapeutics PLC Result of AGM (2209Y)
December 29 2023 - 4:49AM
UK Regulatory
TIDMSBTX
RNS Number : 2209Y
SkinBioTherapeutics PLC
29 December 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Company")
Results of AGM
29 December 2023 - SkinBioTherapeutics plc (AIM: SBTX or the
"Company") announces that at the Company's Annual General Meeting,
held today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the
Company's Registrar are set out below:
Resolution For & Discretionary Against Withheld
Number % Number % Number %
of votes of votes of votes
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
to receive and
adopt the directors'
and auditors'
report and the
financial statements
for year ended
01 30 June 2023 43,029,848 96.78% 1,413,649 3.18% 17,051 0.04%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for Gravita Audit
Limited to be
re-appointed
as the auditors
of the Company
until the next
02 AGM 42,677,600 95.99% 448,075 1.01% 1,334,873 3.00%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for the Directors'
to be authorised
to fix the auditors'
03 remuneration 42,958,431 96.62% 186,707 0.42% 1,315,410 2.96%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for Stuart Ashman
to be re-elected
as a Director
04 of the Company 39,303,678 88.40% 2,636,183 5.93% 2,520,687 5.67%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for Martin Hunt
to be re-elected
as a Director
05 of the Company 39,991,885 89.95% 2,248,346 5.06% 2,220,317 4.99%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for Dr Catherine
Prescott to be
re-elected as
a Director of
06 the Company 40,063,946 90.11% 3,072,834 6.91% 1,323,768 2.98%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for Danielle
Bekker to be
re-elected as
a Director of
07 the Company 42,059,615 94.60% 972,653 2.19% 1,428,280 3.21%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
for Manprit Singh
Randhawa to be
re-elected as
a Director of
08 the Company 39,716,379 89.33% 2,419,340 5.44% 2,324,829 5.23%
------------------------- ------------- ------- ---------- ------ ---------- ------
Ordinary resolution
to authorise
the directors
09 to allot shares 42,030,813 94.54% 1,096,351 2.47% 1,333,384 3.00%
------------------------- ------------- ------- ---------- ------ ---------- ------
Special resolution
to authorise
the directors
to disapply pre-emption
10 rights 42,285,656 95.11% 822,045 1.85% 1,352,847 3.04%
------------------------- ------------- ------- ---------- ------ ---------- ------
Special resolution
to authorise
the directors
to disapply pre-emption
rights in relation
to an acquisition
or other capital
11 investment 42,302,981 95.15% 804,720 1.81% 1,352,847 3.04%
------------------------- ------------- ------- ---------- ------ ---------- ------
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191 495 7325
Stuart J . Ashman, CEO
Manprit Randhawa, CFO
Cavendish Capital Markets Limited Tel: +44 (0) 20 7220 0500
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
Instinctif Partners (financial Tel: +44 (0) 20 7457 2020
press) SkinBioTherapeutics @instinctif.com
Melanie Toyne-Sewell / Jack Kincade
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R) , is based upon discoveries made by Professor
Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors,
the most advanced of which are cosmetic skincare and food
supplements to modulate the immune system by harnessing the
gut-skin axis. In each area SkinBioTherapeutics plans to exemplify
its technology through human studies. The Company's first product,
AxisBiotix-Ps(TM), a food supplement to address the symptoms of
mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in
Newcastle, UK. For more information, visit :
www.skinbiotherapeutics.com and www.axisbiotix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGNKCBQKBDDCBB
(END) Dow Jones Newswires
December 29, 2023 05:49 ET (10:49 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
